Xeris Biopharma Holdings Inc (XERS)
2.24
-0.02
(-0.88%)
USD |
NASDAQ |
Jun 28, 16:00
2.245
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Cash from Operations (Quarterly): -20.30M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -20.30M |
December 31, 2023 | 7.471M |
September 30, 2023 | -14.61M |
June 30, 2023 | -13.74M |
March 31, 2023 | -26.14M |
December 31, 2022 | -16.12M |
September 30, 2022 | -17.75M |
June 30, 2022 | -20.61M |
March 31, 2022 | -48.41M |
December 31, 2021 | -28.95M |
September 30, 2021 | -22.61M |
June 30, 2021 | -20.02M |
March 31, 2021 | -23.96M |
December 31, 2020 | -10.87M |
September 30, 2020 | -16.98M |
Date | Value |
---|---|
June 30, 2020 | -23.76M |
March 31, 2020 | -28.94M |
December 31, 2019 | -29.57M |
September 30, 2019 | -30.58M |
June 30, 2019 | -23.04M |
March 31, 2019 | -21.15M |
December 31, 2018 | -18.34M |
September 30, 2018 | -15.92M |
June 30, 2018 | -14.22M |
March 31, 2018 | -7.805M |
December 31, 2017 | -9.10M |
September 30, 2017 | -5.577M |
June 30, 2017 | -6.467M |
March 31, 2017 | -3.519M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-48.41M
Minimum
Mar 2022
7.471M
Maximum
Dec 2023
-21.39M
Average
-20.61M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
AVITA Medical Inc | -20.86M |
INmune Bio Inc | -7.476M |
NovaBay Pharmaceuticals Inc | -1.572M |
Palatin Technologies Inc | -8.607M |
iBio Inc | -3.654M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -19.65M |
Cash from Financing (Quarterly) | 35.19M |
Free Cash Flow | -43.38M |
Free Cash Flow Per Share (Quarterly) | -0.1457 |
Free Cash Flow to Equity (Quarterly) | -59.21M |
Free Cash Flow to Firm (Quarterly) | -15.27M |
Free Cash Flow Yield | -13.98% |